

**BILL SUMMARY**  
1<sup>st</sup> Session of the 60<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>HB1416</b>
<b>Version:</b>	<b>FA1</b>
<b>Request Number:</b>	
<b>Author:</b>	<b>Rep. Caldwell</b>
<b>Date:</b>	<b>3/3/2025</b>
<b>Impact:</b>	<b>HealthChoice Plan: \$3,000,000</b>

**Research Analysis**

Pending

Prepared By: House Research Staff

**Fiscal Analysis**

In its current form, HB 1416 requires a group insurance plan to provide a Preferred Drug List (PDL) with non-opioid drugs for pain management on equal terms with opioids, so they are not disadvantaged or discouraged.

Officials from the Employees Group Insurance Division estimate the impact on the HealthChoice plan to cost up to Three Million Dollars (\$3,000,000) annually if novel treatments are approved and gain significant utilization. Officials stated, "There are new treatments in the non-opioid being approved/considered for approval that aim to reduce pain without the addictive risk profile. These medications will likely be very expensive versus traditional non-opioid treatments (Advil, Tylenol). Depending on the uptake in the market, long-term safety and other variables, these medications could have significant longer-term financial impact on the plan, as a class."

Therefore, the fiscal impact for the FY-26 state budget is anticipated to be \$3,000,000.

The floor amendment to strike title does not change the fiscal impact of the measure.

Prepared By: Alexandra Ladner, House Fiscal Staff

**Other Considerations**

None.